A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema - Sultan, Marla B.; Zhou, Duo; Loftus, Jane; Dombi, Theresa; Ice, Kathleen S. (Ophthalmology (Rochester, Minn.), 2011)
Keywords: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide - administration & dosage; Biological and medical sciences; Diabetes. Impaired glucose tolerance; Diabetic Retinopathy - complications; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Dose-Response Relationship, Drug; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Fluorescein Angiography; Fundus Oculi; Humans; Intravitreal Injections; Macula Lutea - pathology; Macular Edema - drug therapy; Macular Edema - etiology; Macular Edema - physiopathology; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Retinopathies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Young Adult; Endocrinopathy; Retinopathy; Phase; Diabetes mellitus; Mask; Retinal edema; Pegaptanib; Eye disease; Vascular endothelium growth factor; Treatment; Sodium; Oligonucleotide; Ophthalmology; Pegylated form; Antiangiogenic agent